Drug Discovery Today
SEPTEMBER 22, 2021
AstraZeneca scientists, based in Cambridge UK, have analysed over 18,000 phenotypes in combination with whole exome sequencing data from nearly 300,000 UK Biobank research participants.
Drug Patent Watch
SEPTEMBER 20, 2021
I’ll be leading a workshop on generic portfolio management, and also giving a talk, at the 14th annual Marcus Evans event on Portfolio Planning and Partnerships for Generics. The event…. The post Workshop and lecture on generic portfolio management appeared first on DrugPatentWatch - Make Better Decisions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
SEPTEMBER 23, 2021
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Update: Buy-and-Bill Market Trends. Click here to see the original post and comments from May 2021. Last week, Cigna released its earnings for the first quarter of 2021. Links below. I was struck by how quickly Cigna’s Express Scripts PBM business has increased revenues and prescriptions from its retail pharmacy network.
The Strateos Blog: Drug Discovery
SEPTEMBER 24, 2021
On September 15th, Strateos hosted Part 2 of its Chemistry Webinar Series: Remote Access Robotic Controlled Compound Synthesis. In continued efforts to provide scientists with end-to-end technologies to accelerate their workflows, Strateos has expanded its synthetic chemistry solutions with the integration of PerkinElmer Informatics Signals™ electronic lab notebook (ELN).
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Tebu Bio: Drug Discovery
SEPTEMBER 23, 2021
Propelled into the spotlight by the COVID-19 pandemic, mRNA has become a biological entity of great interest in drug discovery - yet mRNA vaccination is just the beginning of more and more discoveries and applications.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Channels
SEPTEMBER 20, 2021
Informa Connect's Pharma/Biotech GTN Summit. Hybrid Event In-Person: November 17-19, 2021 in Philadelphia Virtual: November 22-23, 2021 www.informaconnect.com/gtn. Join the life sciences community this fall at Informa Connect’s GTN Summit , now in the 11th year. Whether you register with an All-Access Pass (attending in-person on November 17-19, 2021 with access to Virtual content) or register with a Virtual Pass (attending from your home or office on November 22-23, 2021 with access to the In-P
Pharmaceutical Development Group
SEPTEMBER 20, 2021
Introduction: Devices exempted under 510(k) state if the device offers safety and is highly effective on the consumers under the FDA. Exempted Devices which get relaxation by 510(k) are classified by the FDA into Class I type, Class II type, and Class III type. There are specific regulations mentioned with each generic type of device. The classification regulations, however, come over various categories of devices.
Drug Patent Watch
SEPTEMBER 18, 2021
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Finland. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Finland? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 23, 2021
Annual Drug Patent Expirations for SAXENDA Saxenda is a drug marketed by Novo and is included in one NDA. It is available from two suppliers. There are twenty-two patents protecting…. The post New patent for NOVO drug SAXENDA appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Channels
SEPTEMBER 21, 2021
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Update: Buy-and-Bill Market Trends. Click here to see the original post and comments from May 2021. BTW, my prediction about AllianceRx Walgreens Prime is already starting to come true. Prime Therapeutics recently alleged that Walgreens is competing against the companies' joint venture.
Drug Channels
SEPTEMBER 24, 2021
This week, I’m rerunning some popular posts while I prepare for today's live video webinar: Drug Channels Update: Buy-and-Bill Market Trends. Click here to see the original post and comments from June 2021. The Bureau of Labor Statistics (BLS) has recently released its employment and salary data for 2020. That means it’s time to update Drug Channels Institute’s (DCI) annual analysis of pharmacist salaries and employment.
Drug Patent Watch
SEPTEMBER 24, 2021
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Spain. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Spain? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 24, 2021
Annual Drug Patent Expirations for GENOSYL Genosyl is a drug marketed by Vero Biotech and is included in one NDA. There are nineteen patents protecting this drug. This drug has…. The post New patent for Vero Biotech drug GENOSYL appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
SEPTEMBER 24, 2021
Annual Drug Patent Expirations for IMVEXXY Imvexxy is a drug marketed by Therapeuticsmd Inc and is included in one NDA. It is available from one supplier. There are twelve patents…. The post New patent for Therapeuticsmd Inc drug IMVEXXY appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 23, 2021
This chart shows the pharmaceutical companies with the most patents in Hungary. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Hungary? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 23, 2021
Annual Drug Patent Expirations for CONTRAVE Contrave is a drug marketed by Nalpropion and is included in one NDA. It is available from three suppliers. There are fourteen patents protecting…. The post New patent for Nalpropion drug CONTRAVE appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 23, 2021
Annual Drug Patent Expirations for ONIVYDE Onivyde is a drug marketed by Ipsen Inc and is included in one NDA. It is available from one supplier. There are sixteen patents…. The post New patent for Ipsen Inc drug ONIVYDE appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Patent Watch
SEPTEMBER 23, 2021
Annual Drug Patent Expirations for SILENOR Silenor is a drug marketed by Currax and is included in one NDA. It is available from three suppliers. There are twelve patents protecting…. The post New patent for Currax drug SILENOR appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 23, 2021
Annual Drug Patent Expirations for BIJUVA Bijuva is a drug marketed by Therapeuticsmd Inc and is included in one NDA. It is available from one supplier. There are sixteen patents…. The post New patent for Therapeuticsmd Inc drug BIJUVA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 22, 2021
This chart shows the pharmaceutical companies with the most patents in China. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in China? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 22, 2021
Annual Drug Patent Expirations for VELTASSA Veltassa is a drug marketed by Vifor Pharma and is included in one NDA. It is available from one supplier. There are twelve patents…. The post New patent for Vifor Pharma drug VELTASSA appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
SEPTEMBER 22, 2021
Annual Drug Patent Expirations for XARELTO Xarelto is a drug marketed by Janssen Pharms and is included in one NDA. It is available from three suppliers. There are four patents…. The post New patent for Janssen Pharms drug XARELTO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 22, 2021
Annual Drug Patent Expirations for VASCEPA Vascepa is a drug marketed by Amarin Pharms and is included in one NDA. It is available from two suppliers. There are sixty-three patents…. The post New patent for Amarin Pharms drug VASCEPA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 22, 2021
Annual Drug Patent Expirations for OZEMPIC Ozempic is a drug marketed by Novo and is included in one NDA. It is available from three suppliers. There are twenty-two patents protecting…. The post New patent for NOVO drug OZEMPIC appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 22, 2021
Annual Drug Patent Expirations for MAYZENT Mayzent is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are two patents protecting…. The post New patent for Novartis drug MAYZENT appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 21, 2021
Annual Drug Patent Expirations for SPY+AGENT+GREEN+KIT Spy Agent Green Kit is a drug marketed by Novadaq Tech and is included in one NDA. It is available from one supplier. There…. The post New patent expiration for Novadaq Tech drug SPY AGENT GREEN KIT appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
113 
Let's personalize your content